CDK1 and hepatocellular carcinoma: It also exhibited antiproliferative activity in hepatocellular carcinoma (HepG2) cells [91] and hepatoma carcinoma BEL-7402 cells, inducing G2/M cell cycle arrest by upregulating Chk1 and Chk2 while downregulating Cyclin B, CDC25, and CDK1 [92].